Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293770 | 0.75 | MEN1 (0.64) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL29774137 | 0.75 | MEN1 (0.64) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL15211966 | 0.75 | MEN1 (0.64) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL4413578 | 0.75 | KMT2A (0.64) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL2959641 | 0.72 | ALDH1A1 (1.00) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL30711693 | 0.72 | ALDH1A1 (1.00) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL4411556 | 0.71 | KMT2A (0.59) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL15212310 | 0.71 | ALDH1A1 (0.59) | MEN1ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL18986772 | 0.70 | PDE4A (0.33) | — | |
| SCHEMBL18986863 | 0.70 | CYP51A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180355441-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-12-13 | — | — | US | disclosed |
| EP-3390420-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | Centre National De La Recherche Scientifique (FR) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102934-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180355441-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | ERCC5, ERCC1, ERCC4 | MEN1 1623/4885ALDH1A1 3917/4885PKM 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.